Clinical trials: Gallbladder Malignant Neoplasm
Gallbladder Cancer
NGS in Gallbladder Cancer and Response to Treatment
Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes.
- Trial name
- NCT05404347
- Testing
- Next generation sequencing
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Banaras Hindu University
Gallbladder Cancer
UCAD for Diagnosing Benign or Malignant Gallbladder Diseases and Follow-up
Copy number variation(CNV) refers to ongoing chromosome segregation errors throughout consecutive cell divisions. CNV is a hallmark of human cancer, and it is associated with poor prognosis, metastasis, and therapeutic…
- Trial name
- NCT06232538
- Testing
- The level of CNV
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Gallstone, Gallbladder Cancer
Global Evaluation of Cholecystectomy Knowledge and Outcomes
Cholecystectomy is amongst the most common surgical operations performed worldwide. Surgical candidates are treated for biliary pathologies, such as biliary colic, cholecystitis and gallstone pancreatitis.
- Conditions
- Gallstone, Gallbladder Cancer, Bile Duct Injury
- Trial name
- GECKO (NCT06223061)
- Where
- United Kingdom
- Volunteers
- 53,708 people
- Sponsor
- University of Edinburgh
Biliary Tract Cancer, Cholangiocarcinoma
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
The study to evaluate M7824 monotherapy in participants with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT03833661
- Testing
- M7824
- Where
- 33 sites in United States, China and 7 more
- Volunteers
- 159 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc)
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic…
- Conditions
- Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- NCT07793253
- Testing
- Daraxonrasib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins